Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. - Wikidata - wikimedia - TriplyDB

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

http://www.wikidata.org/entity/Q44771716

about

Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview Ustekinumab for the treatment of Crohn's disease.Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.Adverse events in IBD: to stop or continue immune suppressant and biologic treatment Biological therapy for dermatological manifestations of inflammatory bowel disease A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.Biologic agents for IBD: practical insights.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?Skin Manifestations of Inflammatory Bowel Disease.The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.Digestive system in psoriasis: an update.Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.Anti-TNF associated psoriasis.Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.

P2860

Q22305935-190E39F8-A6B1-44DC-94CD-2166120672C0 Q26738918-02762DD4-8745-4114-A0F3-D9F02D48C115 Q30390909-4107B30C-66DE-42F8-A2E8-C626576FEAE9 Q33829739-25163D1A-EF0B-45EC-84D3-A46FE3D38AAD Q34073191-21564ABC-CB24-4D5F-A3A4-FA0AA5A0C60C Q35058744-B02BA127-42C1-450A-8017-92601F463879 Q35100143-122DBECE-7D7B-4BA7-B82C-F59076D50A1F Q36202783-B2779BB9-F6DC-46FA-8D6F-17C6FADCDF20 Q36586054-B0A50328-634E-414D-B06E-49C02AB8FB01 Q37016608-9843789D-9399-44E4-849B-AF4956A3BF01 Q37329074-2F48D164-27E2-4619-BB78-58E4A2828F13 Q38024281-B9A81939-34A8-4052-9F97-56A4CAC5FDCD Q38049779-E1744873-7868-431A-A913-911D32229B3D Q38050938-50ADFAEE-27B6-46DF-91FE-65A10B259C50 Q38099727-5C43404D-CA21-4E0A-A1AE-5A9CFECC2649 Q38179468-BD46D017-8039-4FC0-9C07-47DC969FF1F9 Q38315640-7B3A2E74-372E-445A-9D42-663A66EB2B0F Q38394816-F0BD0198-1658-4039-A5DC-88A751A87425 Q38425063-C245536F-5CC4-4AC3-80EA-769E0B615F5B Q38568898-E0A27631-F38A-434F-AF31-9F6F3F03BDAD Q38630959-06CAF683-18E8-45CF-AB2D-3617B46D9D59 Q38707864-85AE2BA9-0E8A-4AD0-92E2-8988C8416757 Q38751610-51D648D4-C990-4B5A-B87F-C6A2167F5675 Q39361308-3C69840F-979B-4888-98D7-B41FEA20563C Q40791552-239F568B-2A74-4CBC-B137-D974D9F2077E Q40792685-A5E27E4D-1903-44E6-BF1D-ACA1460BD57B Q41520678-D3AAB961-34C5-4E4A-9388-D13811E73388 Q42074843-3587BAE3-7519-42F5-8E89-6B25FB90968B Q44379124-F238ACA1-304E-4448-B55C-7B3B34F23429 Q44390503-A4A217BC-54FA-4045-8269-FA239F2D0370 Q44803722-F1E913D8-2734-4566-A540-2624EFCA0C43 Q45062333-28C9ECB0-7BE6-4834-A5F0-377602E348D9 Q46466020-00AB4109-D900-4EF9-B3E1-C77C1CC67297 Q48102896-BD4374B6-8F3D-4692-8CC2-09EFEA678B1B Q49970991-25F6A448-DD65-4E2E-998B-E14D61400C28 Q50681708-6C19381E-40F7-49EA-A769-C1FA98DF432F Q50986864-E9DC941A-C0A1-4C5E-ABB0-0F15522B033A Q51565778-5E33C692-014D-41E5-A0F0-5FD712D2DBBD Q52844436-A56DC6F4-5847-4E58-9CAD-B079F770A0FE Q53228858-B9B278EE-806A-44C8-A14D-BF95DF438561

P2860

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

http://www.wikidata.org/entity/Q44771716

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@en

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@nl

type

label

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@en

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@nl

prefLabel

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@en

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@nl

P1433

Q44771716-FB36F76E-2FCA-4C32-BECB-EA3C28F1DB87

P1476

Q44771716-106ADA77-8841-4B92-92A3-C67E4113BD99

P2093

Q44771716-02B4550C-9A7D-4AB4-A771-A0FC47113A9E

Q44771716-16D91455-8097-4824-A9AD-64643CCAE401

Q44771716-2732ACEE-A1C7-4121-978B-5A8DFF59277E

Q44771716-43062574-31A2-40D3-83FF-649B3229EBE7

Q44771716-455183D2-EAB9-4AC9-A622-B839EE81288F

Q44771716-6FEE05FF-423F-452C-910E-68E1FBADA303

Q44771716-81562143-6048-4E5F-90DA-04A8BFD1421E

Q44771716-8E12E591-A4D3-407A-BC0F-D11C1AB94D9D

Q44771716-98DEB809-FEB7-474A-99B3-AE132E796AF5

Q44771716-A74D2495-D731-4BA1-9D7B-9CF669A59AB3

P304

Q44771716-56DD9EDC-1758-4C83-A55A-E39750092F96

P31

Q44771716-BA77E08F-CB7E-4072-9B50-87F5ED0F02F2

P356

Q44771716-B7915DC7-1AEC-4D56-BC10-569D540C808B

P407

Q44771716-93BFFC00-1854-44BD-B647-94B0338F623A

P433

Q44771716-A42F4842-F15F-4ECE-A5FC-F2C0FCA130FB

P478

Q44771716-71CBEE70-EF91-45A2-8E83-78D99F3C966B

P50

Q44771716-1AA6D00D-A4DB-46BF-8F3D-63E5D84CA3BB

Q44771716-3C041380-AB8F-4805-95E4-A750E70A9DF9

Q44771716-E113CE37-B1A4-4B24-A2AB-6735BDE5CC58

P577

Q44771716-4C0CCF03-7CBA-4B4B-958C-8FFF2D9FBD7B

P5875

Q44771716-B25FAEA4-1DC0-47AB-90A7-9AE698FB5632

P698

Q44771716-967AC4BE-72EA-4DA9-962A-C4D1B5C15B1F

P921

Q44771716-65D69B31-478D-4190-966A-720308E77EEC

P356

J.CGH.2010.07.022

P1433

Clinical Gastroenterology and Hepatology

P1476

Severe skin lesions cause pati ...... tumor necrosis factor therapy.

@en

P2093

Bernard Duclos

http://www.w3.org/2001/XMLSchema#string

David Laharie

http://www.w3.org/2001/XMLSchema#string

Edouard Louis

http://www.w3.org/2001/XMLSchema#string

Emmanuel Delaporte

http://www.w3.org/2001/XMLSchema#string

Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)

http://www.w3.org/2001/XMLSchema#string

Jacques Cosnes

http://www.w3.org/2001/XMLSchema#string

Jean-François Rahier

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Reimund

http://www.w3.org/2001/XMLSchema#string

Marc Lémann

http://www.w3.org/2001/XMLSchema#string

Matthieu Allez

http://www.w3.org/2001/XMLSchema#string

P304

1048-1055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2010.07.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Laurent Peyrin-Biroulet

P577

2010-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45799042

http://www.w3.org/2001/XMLSchema#string

P698

20728573

http://www.w3.org/2001/XMLSchema#string

P921